TY - JOUR T1 - Molecular landscape of pelvic organ prolapse provides insights into disease etiology and clues towards putative novel treatments JF - medRxiv DO - 10.1101/2020.03.12.20034165 SP - 2020.03.12.20034165 AU - Kirsten B. Kluivers AU - Sabrina L. Lince AU - Alejandra M. Ruiz-Zapata AU - Rufus Cartwright AU - Manon H. Kerkhof AU - Joanna Widomska AU - Ward De Witte AU - Wilke M. Post AU - Jakub Pecanka AU - Lambertus A. Kiemeney AU - Sita H. Vermeulen AU - Jelle J. Goeman AU - Kristina Allen-Brady AU - Egbert Oosterwijk AU - Geert Poelmans Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/16/2020.03.12.20034165.abstract N2 - Background Pelvic organ prolapse (POP) represents a major health care burden in women but its underlying pathophysiological mechanisms have not been elucidated.Objective To integrate the results from a large scale exome chip study with published genetic and expression data into a molecular landscape of POP.Design, setting, and participants The exome chip study was conducted in 526 women with POP and 960 healthy controls. To corroborate the findings, we analysed differential gene expression data from 12 POP patients. Vaginal fibroblasts from 4 women with POP were used to test the effect of the anti-diabetic drug metformin.Outcome measurements and statistical analysis The exome chip study used a case-control design to identify single nucleotide variants (SNVs) associated with POP after Bonferroni correction. The molecular landscape was built using the UniProt and PubMed databases to identify functional interactions between the POP candidate genes/proteins. We performed enrichment and upstream regulator analyses of the differentially expressed genes. The effect of metformin in fibroblasts was assessed using one-sample t-test.Results and limitations We found significant association between POP and SNVs in 54 genes. The proteins encoded by 26 of these genes fit into a molecular landscape, together with 37 other POP candidate molecules and two POP-implicated microRNAs. This landscape is located in and around epithelial cells and fibroblasts of the urogenital tract and harbors four interacting biological processes - epithelial-mesenchymal transition, immune response, modulation of the extracellular matrix, and fibroblast function - that are regulated by sex hormones and TGFB1. Based on the landscape, we predicted and showed that metformin alters gene expression in fibroblasts of POP patients in a beneficial direction. The main limitation of our study is that we have no independent replication of the exome chip results.Conclusions The integrated molecular landscape of POP that we built provides insights into the biological processes underlying the disease and clues towards novel treatments.Patient summary We reported the first exome chip study of POP and combined the genes identified in this study with other data from the literature to build a ‘molecular landscape’ of POP. This landscape will advance our understanding of the disease and may lead to novel treatments.Competing Interest StatementGP is director of Drug Target ID, Ltd. He nor any of the other contributing authors have any conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript.Funding StatementFunding/Support and role of the sponsor The exome chip data for the patients and NBS controls were generated in a research project that was financially supported by BBMRI-NL, a Research Infrastructure financed by the Dutch government (NWO 184.021.007) (https://www.nwo.nl/). Co-author KAB was supported by NIH grant RO1 HD061821 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (https://www.nih.gov/). Co-authors KBK, AMRZ, JW, WDW, WMP, EO and GP were supported by the European Fund for Regional Development (EFRD) (https://ec.europa.eu/regional_policy/en/funding/erdf/) under grant agreement no. PROJ00787 (DIABIP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Acknowledgments We would like to thank all subjects - both patients and healthy controls - for their active participation in the exome chip study. We thank Mark E. Vierhout, emeritus professor in urogynaecology at Radboud university medical center, Nijmegen, The Netherlands, as well as Leon van Kempen, COO and Scientific Director of the Molecular Pathology Center at Jewish General Hospital, QC, Canada and Jeroen Dijkstra, Lead Quality Assurance Officer and Research Technician at Radboud university medical center, since they all had an important role in candidate gene association studies of POP, which has eventually resulted in this paper. Furthermore, we would like to thank the principal investigators of the Nijmegen Biomedical Study (NBS), i.e. the co-author LAK as well as B. Franke, A.L.M. Verbeek and D.W. Swinkels.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary material. Any extra information is available from the corresponding author, upon reasonable request. ER -